<DOC>
	<DOCNO>NCT01339143</DOCNO>
	<brief_summary>The purpose study compare effect vildagliptin vs. pioglitazone oxidative stress daily blood glucose fluctuation , patient type 2 diabetes inadequately control metformin .</brief_summary>
	<brief_title>Compare Effect DPP-IV Inhibitor TZD Glycemic Variability Oxidative Stress Patient With 2 Diabetes</brief_title>
	<detailed_description>Activation oxidative stress glucose fluctuation play major role pathogenesis diabetic complication . Dipeptidyl peptidase IV ( DPP-IV ) , vildagliptin , enhance glucose-induced insulin secretion , decrease glucagon secretion , reduce postprandial hyperglycemia may also improve acute fluctuation glucose . We believe vildagliptin may exert effect decrease oxidative stress reduce glucose excursion .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>Male female age 1880 year Type 2 diabetes mellitus On stable dose metformin ( 1000mg ) least 1 month HbA1c 7~10 % Subjects statins , ACE inhibitor , ARBs antioxidant allow long stable dos compound dosage change course study BP control change require BP medication Agreement maintain prior diet &amp; exercise Type 1 DM Any kind secondary DM Pregnant lactate woman . Treatment sulfonylurea , Î±glucosidase inhibitor , glinide , GLP1 analogues , DPPIV inhibitor insulin therapy within 1 month prior informed consent . Treatment rosiglitazone pioglitazone within 3 month prior inform consent . HbA1c &lt; 7 % &gt; 10 % Uncontrolled hypertension ( BP &gt; 160/100 mmHg ) Congestive heart failure ( NYHA class I IV ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Vildagliptin</keyword>
</DOC>